Hasan Shirin, Mosier Michael J, Szilagyi Andrea, Gamelli Richard L, Muthumalaiappan Kuzhali
Department of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
Surgery. 2017 Oct;162(4):901-916. doi: 10.1016/j.surg.2017.06.001. Epub 2017 Jul 14.
Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.
Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.
Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.
The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.
危重病性贫血对外源性促红细胞生成素具有抵抗性。输注浓缩红细胞是唯一的治疗选择,尽管存在相关成本和发病率,但仍需要替代策略。红细胞发育可分为促红细胞生成素依赖性和促红细胞生成素非依赖性阶段。我们之前已经表明,烧伤患者促红细胞生成素依赖性发育是完整的,而由β1/β2-肾上腺素能机制调节的促红细胞生成素非依赖性早期定向阶段受到损害。利用烫伤损伤模型,我们研究了促红细胞生成素非依赖性晚期成熟阶段以及β1/β2、β-2或β-3阻断对烧伤介导的促红细胞生成素抵抗性贫血的影响。
将烧伤小鼠随机分为接受普萘洛尔(非选择性β1/β2拮抗剂)、纳多洛尔(长效β1/β2拮抗剂)、布托沙明(选择性β2拮抗剂)或SR59230A(选择性β3拮抗剂)每日注射,持续6天。通过流式细胞术使用CD71、Ter119和Syto-16将总骨髓细胞表征为非红细胞、早幼红细胞和晚幼红细胞、有核正染红细胞和无核网织红细胞亚群。对多能祖细胞进行MafB表达细胞检测。
虽然普萘洛尔改善了早幼红细胞和晚幼红细胞,但只有布托沙明和选择性β3拮抗剂给药在外周血血红蛋白和红细胞计数上有积极反映。虽然烧伤阻碍了早期定向和晚期成熟阶段,但β1/β2拮抗作用通过β2特异性MafB调节在整个定向阶段增加了早幼红细胞。β3拮抗作用在改善整个晚期成熟阶段的总体红细胞方面更有效。
该研究揭示了烧伤后协调促红细胞生成素抵抗性贫血的新的β2和β3肾上腺素能机制,它们分别阻碍早期定向阶段和晚期成熟阶段。